Publications by authors named "Yabing Guo"
Article Synopsis
- TACE is the standard treatment for patients with unresectable, non-metastatic hepatocellular carcinoma, and this study evaluates the effectiveness of adding lenvatinib and pembrolizumab to TACE compared to a placebo.
- The multicenter, randomised, double-blind phase 3 study (LEAP-012) involved participants from 137 sites across 33 countries who were randomly assigned to receive either TACE with the new drugs or TACE with a placebo.
- The primary endpoints were progression-free survival and overall survival, and the results reported are from the first interim analysis, which serves as the final analysis for progression-free survival.
Article Synopsis
- * Out of 71 patients, the objective response rate (ORR) was 9.9%, with a disease control rate of 36.6% and a median duration of response of 10.7 months.
- * The treatment was associated with a significant incidence of adverse events, with 73.2% reporting treatment-related complications, but overall, iparomlimab demonstrated preliminary efficacy and a manageable safety profile.
Article Synopsis
- Sitravatinib is a targeted treatment for advanced cancers, specifically focusing on TAM receptors and others, and was tested in a study (SAFFRON-104) for its effectiveness alone or with another drug (tislelizumab) in advanced liver or stomach cancers.
- The study included 111 patients, and the recommended dosage of sitravatinib was established at 120 mg daily. Results showed that about 25% of patients experienced a positive response to sitravatinib alone, while those receiving it with tislelizumab had lower response rates.
- Overall, the combination of sitravatinib and tislelizumab was generally safe with manageable side effects, indicating preliminary
Article Synopsis
- Lenvatinib is commonly used to treat unresectable hepatocellular carcinoma (uHCC), but its combination with the immunotherapy drug tislelizumab was evaluated for effectiveness and safety in this study.
- In a phase 2 study involving 64 systemic treatment-naïve patients, no dose-limiting toxicities were reported, and the combination treatment showed significant antitumor activity, achieving a 38.7% objective response rate.
- With a median follow-up of 15.7 months, the treatment had an 88.6% overall survival rate at 12 months and was well-tolerated, making it a promising first-line option for patients with uHCC.
Background: Artificial intelligence (AI)-assisted clinical trial screening is a promising prospect, although previous matching systems were developed in English, and relevant studies have only been conducted in Western countries. Therefore, we evaluated an AI-based clinical trial matching system (CTMS) that extracts medical data from the electronic health record system and matches them to clinical trials automatically.
Methods: This study included 1,053 consecutive inpatients primarily diagnosed with hepatocellular carcinoma who were referred to the liver tumor center of an academic medical center in China between January and December 2019.
Article Synopsis
- Primary liver cancer is a major health concern in China, with hepatocellular carcinoma accounting for 75-85% of cases, ranking as the fourth most common cancer and the second leading cause of cancer-related deaths in the country.
- The Guidelines for Diagnosis and Treatment of Primary Liver Cancer were first published in 2017 and have been updated due to new research and evidence in the field, leading to the 2022 Edition written by over 100 experts.
- The updated guidelines aim to promote evidence-based practices to enhance the 5-year survival rate of liver cancer patients in alignment with the "Health China 2030 Blueprint."
Article Synopsis
- Hepatocellular carcinoma (HCC) is a major cause of cancer deaths, and there is a need for new first-line treatment options; tislelizumab, a PD-1 inhibitor, shows promise as a second-line treatment.
- The RATIONALE-301 clinical trial compares the efficacy and safety of tislelizumab and sorafenib in treating unresectable HCC in newly diagnosed patients.
- Results indicate that tislelizumab meets the criteria for noninferiority in overall survival compared to sorafenib, with a median overall survival of 15.9 months vs. 14.1 months; however, it did not demonstrate superiority, while showing a higher objective response rate (14.3%
Background: Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not in hepatocellular carcinoma. Therefore, a clinical study was conducted to compare the efficacy and safety of the anti-PD-1 antibody camrelizumab plus the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
Methods: This randomised, open-label, international phase 3 trial (CARES-310) was done at 95 study sites across 13 countries and regions worldwide.
Liver fibrosis is a wound-healing response that arises from various aetiologies. Flavonoid compounds have been proved of their anti-liver fibrosis effects. This study aimed to elucidate the protective effect and mechanism of flavonoid compound GL-V9 on CCl-induced and DDC-induced liver fibrosis.
View Article and Find Full Text PDFBackground: In the global REACH-2 study, ramucirumab significantly improved overall survival (OS) compared with placebo in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). REACH-2 China study aimed to evaluate the efficacy and safety of ramucirumab in Chinese patients with advanced HCC (NCT02435433).
Methods: REACH-2 China was a randomised, double-blind, placebo-controlled, phase 3 study done at 31 centres in China between Sep 16, 2015, and March 15, 2021.
Background: Combining an antiangiogenic agent with an anti-PD-1 agent is a promising strategy for unresectable hepatocellular carcinoma (HCC).
Aims: To explore the effectiveness and tolerability of lenvatinib plus camrelizumab vs. lenvatinib monotherapy as a first-line treatment for unresectable HCC.
Background: Whether serum hepatitis B virus (HBV) RNA associates with hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients has not been fully elucidated.
Methods: We enrolled 2974 patients receiving nucleos(t)ide analogues (NAs) from a prospective, observational CHB cohort to investigate the effect of serum HBV RNA, measured at study entry (baseline), on HCC development, using Cox regression analyses.
Results: During median follow-up of 4.
The responses of forests to nitrogen (N) deposition largely depend on the fates of deposited N within the ecosystem. Nitrogen-fixing legume trees widely occur in terrestrial forests, but the fates of deposited N in legume-dominated forests remain unclear, which limit a global evaluation of N deposition impacts and feedbacks on carbon sequestration. Here, we performed the first ecosystem-scale N labeling experiment in a typical legume-dominated forest as well as in a nearby non-legume forest to determine the fates of N deposition between two different forest types and to explore their underlying mechanisms.
View Article and Find Full Text PDFBackground: To compare the treatment effectiveness and safety among transarterial infusion chemotherapy (TAI) with FOLFOX regimen, transarterial chemoembolization (TACE), and sorafenib in patients with BCLC stage C hepatocellular carcinoma (HCC).
Methods: The data of consecutive patients with BCLC stage C HCC treated with TAI, TACE, or sorafenib from January 2015 to December 2018 at three centers were retrospectively analyzed. Propensity-score matched (PSM) analysis was pairwise performed to reduce selection bias.
Background: China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase 2-3 ORIENT-32 study aimed to assess sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma.
View Article and Find Full Text PDFMicroRNAs are a group of endogenous small non-coding RNAs commonly dysregulated in tumorigenesis, including glioblastoma (GBM), the most malignant brain tumor with rapid proliferation, diffuse invasion, and therapeutic resistance. Accumulating evidence has manifested that miR-1258 exerts an inhibitory role in many human cancers. However, the expression pattern of miR-1258 and its potential function in GBM tumorigenesis remain unclear.
View Article and Find Full Text PDFBackground: GLS-010, a novel engineered fully human immunoglobin G4 monoclonal antibody, can specially block the PD-1/PD-L1/2 axis and reactivate the antitumor immunity.
Aim: This phase Ia/Ib study was carried out to evaluate the safety, recommended phase II dose (R2PD), and primary antitumor effects of GLS-010 in patients with advanced, refractory lymphoma and solid tumors.
Methods: In phase Ia study, patients with refractory solid tumors and lymphoma enrolled and received GLS-010 at a dose of 1, 4, or 10 mg/kg Q2W; 240 mg Q3W or Q2W.
Article Synopsis
- This study addresses the lack of research on how radiomics can predict the effectiveness of anti-PD-1 therapy in patients with Hepatocellular Carcinoma (HCC).
- Researchers aimed to create a radiomics nomogram using pretreatment CT images and clinical risk factors to evaluate treatment efficacy in advanced HCC patients.
- Based on data from 58 patients, the developed nomogram showed strong performance with an AUC of 0.894 in the training set and 0.883 in the validation set, indicating its potential as a useful tool for predicting treatment outcomes.
Introduction: Previous trials demonstrated that anti-angiogenesis or anti-programmed death protein 1 (PD-1) monotherapy showed unsatisfied effect in advanced hepatocellular carcinoma (HCC). No study existed that focus on the effects of camrelizumab and apatinib ("C+A") combination therapy for HCC patients with the location and extent of portal vein tumor thrombus (PVTT) as the main variable being assessed. This study was to compare the efficacy and tolerability of "C+A" for HCC patients with PVTT.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigated the safety and effectiveness of PD-1 inhibitors (toripalimab, camrelizumab, sintilimab) in Chinese patients with hepatitis B virus-related hepatocellular carcinoma (HCC), highlighting a need for research in this area.
- - Data from 70 patients showed a 30% objective response rate (ORR) and 72.9% disease control rate (DCR), with significant side effects like rash and fatigue but generally manageable safety profiles.
- - Results indicate that PD-1 immunotherapy presents promising outcomes for this patient group and suggests potential for broader clinical use in treating HCC.
[Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial].
Nan Fang Yi Ke Da Xue Xue Bao
October 2020
Objective: To compare the effects of medical ozone oil and urea ointment for prevention and treatment of hand-foot skin reaction (HFSR) caused by sorafenib in patients with hepatocellular carcinoma (HCC).
Methods: A total of 99 patients diagnosed with advanced HCC according to National Comprehensive Cancer Network (NCCN) who were scheduled to receive sorafenib treatment for the first time were enrolled in this study between April, 2018 and January, 2020. The patients were randomized into medical ozone oil group (=49) and urea ointment group (control group, =49) for treatment with local application of 1 mL medical ozone oil (experimental group) and 10% urea ointment (2 g) on the palm and plantar skin (including the fingers and joints) for 12 weeks (3 times per day) starting at the beginning of sorafenib treatment, respectively.
Background & Aims: There are no data validating the performance of spleen stiffness measurement in ruling out high-risk varices in patients with HBV-related cirrhosis under maintained viral suppression. Thus, we aimed to prospectively validate the performance of spleen stiffness measurement (cut-off 46 kPa) combined with Baveno VI criteria in ruling out high-risk varices in these patients.
Methods: Patients with cirrhosis were enrolled from April to December 2019 at the hepatology unit of the Nanfang Hospital, China.
Background & Aims: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis.
Methods: A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686).
Article Synopsis
- The article from the British Journal of Clinical Pharmacology was published online on July 5, 2020, but has now been withdrawn.
- The withdrawal was mutually agreed upon by the authors and the publisher, John Wiley & Sons Ltd.
- The authors intend to revise their study to include the latest data before resubmitting.
Semi-solid rheology characterization of sludge conditioned with inorganic coagulants.
Water Sci Technol
December 2019
Article Synopsis
- Rheology measurement is utilized to analyze the semi-solid characteristics of sludge in wastewater treatment processes, revealing how coagulants like PAC and FC enhance floc strength.
- The tests show minimal change in rheological behavior despite increased coagulant dosage, indicating interactions among particles lead to a rigid structure rather than affecting the rheological nature.
- An improved viscoelastic model was created to predict sludge behavior, with PAC yielding optimal results while FC did not demonstrate a clear optimum dosage.